Clinical Trial Detail

NCT ID NCT02526017
Title Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Five Prime Therapeutics, Inc.
Indications

melanoma

colorectal cancer

pancreatic cancer

lung non-small cell carcinoma

head and neck squamous cell carcinoma

glioblastoma multiforme

Therapies

Cabiralizumab

Nivolumab

Age Groups: adult

No variant requirements are available.